PATENT CLAIM ANALYSIS

Application Number: 16060020
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["424", "186100"]

Abstract:
Cancer immunotherapy is enhanced by co-expression of cancer associated or tumor-specific (neo)epitopes with co-stimulatory molecules and/or other immune activators. Where desired, treatment may be enhanced by administration of a immune checkpoint inhibitor.

Claim (Index 56):
A method of treating a patient, comprising:\n obtaining a tumor sample and a matched normal sample from the patient; identifying an HLA-type of the patient and identifying a cancer-related neoepitope of the patient; genetically modifying a virus to include (i) a nucleic acid encoding the neoepitope when the binding affinity is below a predetermined threshold value, and (ii) a nucleic acid encoding at least one co-stimulatory molecule; and administering the genetically modified virus to the patient.

Metadata:
- Claim Count in Document: 61.0
- Percentile: 94.0
- Lexical Diversity: 1.15152
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15366838', '15291911', '15291516', '14247298', '15387199']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6602511236321055
- 35 USC 102 Novelty (BERT): 0.5528213809303626
- Combined Prediction Score: 0.6495081493619312
- Mean Citation Score: 286.4204180000001
- Max Citation Score: 412.73987
- Similarity Product: 293.92530884580486

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test